The Latest

  • A stethoscope rests on top of an EKG printout. A cool blue cast dominates the scene.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines

    Pelacarsen didn’t protect heart health despite lowering levels of a protein particle, “Lp(a),” in a large clinical trial — a surprise result with important implications for cardiovascular drug research.

  • Over the shoulder shot of medical scientist working with scan images on a personal computer in laboratory.
    Image attribution tooltip
    gorodenkoff via Getty Images
    Image attribution tooltip
    Sponsored by Dell Technologies & NVIDIA

    Six AI agents, one deskside system: A new model for clinical decision support

    Multi-agent AI reasoning at the point of care, with complete data sovereignty built in.

  • An illustration of B cells producing antibodies
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Immune reset

    Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts

    Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management could help developers avoid future safety hazards.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Roivant surges on ‘exceptional’ results; Bristol Myers touts first-of-its-kind CAR-T therapy

    One analyst views Roivant’s pulmonary hypertension drug as a future $10 billion-plus seller. Elsewhere, AstraZeneca overcame a negative advisory committee vote and Pharvaris claimed success in a key study.

  • A photo of Moonwalk Biosciences' executive team.
    Image attribution tooltip
    Permission granted by Erin Beach
    Image attribution tooltip
    Obesity drugs

    Moonwalk reloads with $70M and new RNAi prospects for obesity

    The California biotech plans to bring its first drug, enabled by licensing technology from a Chinese drugmaker, into clinical testing for obesity by the end of 2027.

  • A double exposure image of a glass flask in a laboratory with stock market information in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    This week in charts: China deals, stock flatlines and Lilly’s M&A spree

    Deals with Chinese drugmakers are continuing at a steady pace, while two mid-cap biotechs' stock prices took a tumble this week. Meanwhile, Lilly has outpaced other pharmas in dealmaking this year.

  • An exterior photo of Seattle Children's Hospital.
    Image attribution tooltip
    Courtesy of Seattle Children's Hospital
    Image attribution tooltip

    BrainChild hauls in $116M to make cell therapies for childhood brain cancers

    Spun out of research at Seattle Children’s Hospital, the startup has brought a CAR-T treatment for a rare and deadly pediatric cancer into mid-stage testing.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Ionis’ rare neurology drug approved; Pfizer inks an ADC deal

    Zanvastro is now the first approved medicine for Alexander disease. Elsewhere, an immune system specialist posted positive results and a cell therapy developer turned to layoffs.

  • The AbbVie logo is prominently displayed on the facade of a sleek, contemporary building surrounded by a clear blue sky.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    Trailing rivals, AbbVie scores win with dual-acting myeloma drug

    The drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes etentamig toward FDA submission.

  • A technician in protective clothing stands beside manufacturing equipment in a pharmaceutical laboratory.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    The hidden scale-out problem behind CAR-T’s growth

    CAR-T’s commercial challenge is making thousands of patient-specific manufacturing runs behave like one reliable system. "In vivo" production techniques could be one solution.

  • An Ultragenyx sign is seen on the side of an office building.
    Image attribution tooltip
    Permission granted by Ultragenyx
    Image attribution tooltip

    Ultragenyx to weigh ‘significant’ cost cuts as Angelman drug fails key study

    The failure of what was once considered a potential blockbuster therapy represents a major setback in a tough-to-treat disease and is forcing Ultragenyx to closely examine its expenses.

  • CAR-T cell therapy uses the body as a manufacturing site to fight cancer
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Immune reset

    Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns

    The deaths of three study participants led Novartis to halt development of rap-cel in multiple indications, while “transient” side effects pushed Bristol Myers to voluntarily pause its zola-cel program.

    Updated Sept. 1, 2026
  • An illustration of two immune checkpoint proteins binding
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Akeso, Summit cancer drug confirms lung cancer survival benefit

    A new data cut of a trial pitting ivonescimab, a bispecific antibody, against Merck’s Keytruda showed the new drug helped people live longer.

  • An illustration of dopamine outside the cell binding to a receptor.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    An AI drug specialist zeroes in on rare forms of obesity

    Superluminal Medicines banked $60 million in funding to support development of a drug designed to work similarly to — but potentially be more selectively than — Rhythm Pharmaceuticals’ marketed medicine Imcivree.

  • An anatomical model of the heart sits on a desk in a doctor's office
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    ESC ‘26: Cytokinetics’ sell-off, Arrowhead’s edge and a heart drug autopsy

    At a big meeting for cardiovascular medicines, Cytokinetics and Arrowhead aimed to separate their drugs from competitors while a failed study pressured Alnylam.

  • A sign with the letters GSK hangs on the side of an office building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    China competition

    GSK wagers up to $1.3B on a different kind of cancer drug

    With its latest foray into China, GSK acquired rights from Hutchmed to an “antibody-targeted therapy conjugate” impacting two well-known cancer drivers, EGFR and KRAS.

  • A sign for the Food And Drug Administration is seen
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    UniQure, after setbacks, seeks FDA approval of Huntington’s gene therapy

    The company is now hoping for an affirmative answer on its application after an unusually turbulent year dealing with U.S. regulators.

  • A sign spelling Novartis hangs on the side of a building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Novartis says MS pill succeeds in two large studies

    Notably, Novartis revealed that remibrutinib wasn’t associated with the kind of liver-related side effects other BTK inhibitors like it have encountered.

  • A technician wearing a blue mask works in a laboratory.
    Image attribution tooltip
    Kevin Frayer via Getty Images
    Image attribution tooltip
    China competition

    Drugs from China are reshaping biotech. Track the licensing deals here.

    Including a new deal with Roche last week, Simcere Pharmaceutical has now inked five cross-border licensing pacts since the start of 2025 that are collectively worth up to $5.66 billion.

    Updated Sept. 2, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Teva claims success in celiac study; BioMarin, Ascendis settle patent dispute

    Teva believes the therapy has “pipeline-in-a-product” potential. Elsewhere, a high-stakes trial was paused and GSK advanced a competitor to Moderna’s flu shot.

  • The North Lawn at the White House in Washington, D.C.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Trump administration

    Mid-cap biotechs join Trump’s latest round of drug pricing deals

    Focused on Medicaid, the new pacts now involve more than just large pharmaceutical companies, but still aren’t expected to meaningfully impact drugmaker profits.

  • A falling line on a stock chart.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Alumis’ TYK2 drug fails in key lupus study

    Though Alumis still sees a path forward in lupus, the result made its drug the latest TYK2 blocker to struggle in conditions beyond psoriasis and psoriatic arthritis. 

  • A double exposure image of a glass flask in a laboratory with stock market information in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    This week in charts: Biotech’s rebound is undeniable

    Not only is the XBI continuing to hover around a historic high, but drug companies can’t seem to get enough of both large IPOs and big-ticket M&A.

  • Illustration of an antibody (immunoglobulin) molecule, showing its Y-shaped structure
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Lilly adds to immune drug pipeline with $2.9B Merida buyout

    The big drugmaker’s latest company acquisition this year is centered around a technology designed to degrade proteins that malfunction in autoimmune disorders.

  • A photo of the packaging for the pancreatic cancer drug Rasonque
    Image attribution tooltip
    Retrieved from Revolution Medicines.
    Image attribution tooltip

    Revolution pancreatic cancer drug should quickly become a blockbuster, analysts say

    Rasonque’s $39,800 monthly list price surpassed Wall Street forecasts and led to rosier sales projections ahead of what one analyst described as a “historic” launch.

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive // IPO window

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    ADARx Pharmaceuticals, which is testing RNA interference drugs for conditions ranging from rare genetic disorders to kidney diseases to stroke prevention, has filed plans for an IPO.

    Updated Sept. 8, 2026